Patients with type 2 diabetes are at increased risk of macro- and microvascular disease. In type 2 diabetes, intensive glycemic control has been associated with a reduction in the risk for lower-extremity amputation (LEA). Improved glycemic control seems to be a strong predictor of decreased risk for subsequent LEA. The Society for Vascular Surgery guidelines suggest that intensive glycemic control (A1c <7) should be targeted. TASC II guidelines suggest targeting an HbA1c goal of <7% (or as close to 6% as possible) in patients with concomitant diabetes and PAD. Society for Vascular Surgery (SVS) suggests a goal of <6.5-7.